Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 2661-2670 Newer>

The Motley Fool January 30, 2006 Stephen D. Simpson	Speed the Plough Schering-Plough is still in a precarious position, but it's likely to have above-average growth. It is also one of the few pharmaceuticals whose risk level is actually decreasing. This could be a stock worth owning for some time.
BusinessWeek February 6, 2006 Amy Barrett	Cracking The Whip At Wyeth Wyeth's R&D chief Robert Ruffolo imposed tough targets on scientists - and it's working.
BusinessWeek February 6, 2006	Bio: Robert Ruffolo A short biography of Wyeth executive Robert Ruffolo.
BusinessWeek February 6, 2006 Gene G. Marcial	If Clinical Trials Pan Out, GTx Could Have A Winner Tiny Biotech GTx is a high-risk stock since it depends on a new drug's outcome.
The Motley Fool January 27, 2006 Stephen D. Simpson	A Real Triumph for Alexion A powerful clinical result brings FDA approval into sight for this biotech company. Investors, enjoy the day -- this is what makes biotech investing fun and exciting.
The Motley Fool January 27, 2006 Stephen D. Simpson	Challenges Needle Novo Nordisk The insulin franchise is attractive, but under threat. Guidance for 2006 wasn't impressive and there are definite challenges ahead. Investors, take note.
The Motley Fool January 26, 2006 Rich Duprey	Will Acquisitions Patch Merck's Pipeline? The pharmaceutical giant announces a biotech shopping spree. A few key acquisitions that contribute late-stage drugs and significant revenue might be all Merck needs to keep its pipeline open. Investors, take note.
The Motley Fool January 26, 2006 Stephen D. Simpson	Will New Drugs Gild Lilly? Although Lilly's late-stage pipeline is weak, newer drugs should still be able to grow. Investors, this is still a mediocre investment option.
The Motley Fool January 25, 2006 Stephen D. Simpson	Is St. Jude Next to Be Wooed? Can St. Jude build upon the jump-start opportunity from Guidant's troubles, or will further market share growth prove to be increasingly hard to come by? Investors, take note.
The Motley Fool January 25, 2006 Rick Casterline	Is BABY Born Again? Natus Medical's 200% growth may be just the beginning. Between its international and domestic efforts, the company is firing on all cylinders. Investors, take note.
<Older 2661-2670 Newer> Return to current articles.